rates is a false equivalence. There are 371 biopharmaceutical companies in the world whose products could be discussed, but more than half of drug mentions refer to a median of six companies that pay these physicians. Moreover, doctors are more positive about drugs whose companies pay them.
Our results raise the concern that financial conflict of interest must be considered with the growing use of social media to discuss cancer products and practices, 1 as well as policies regarding disclosure, divesture, audit and recusal may be considered. VP 
Conflicts of interest in Twitter
We have previously shown that 79·5% of US-based haematologistoncologists on Twitter have at least one financial conflict of interest (FCOI) 1 with the biopharmaceutical industry. However, we did not study whether conflicted physicians tweet about specific products for which they have a FCOI. Using our list of all US-based haematologist-oncologists on Twitter, 1 we focused on the subset of physicians with a FCOI of at least US$1000 in general payments in the year 2014, and at least 100 total tweets. We updated general payment information from the Open Payments website and updated their Twitter activity (number of tweets, followers, following). We excluded users who made their accounts private.
For accounts with less than 300 total tweets, we read all tweets. For accounts with more than 300 tweets, we calculated a "tweet rate" based on usage and read from a timepoint in the past that would approximate 300 tweets. Each tweet or retweet that mentioned an oncology drug with an FDA approval date later than 1996 was recorded. Additionally, we randomly coded 100 tweets regarding drugs for which a conflict existed and 100 for which it did not. We coded these 200 tweets as positive, neutral, or negative. Our study was not submitted for Institutional Board Review as it concerned only publicly available data, and was conducted between Jan 7, to Jan 25, 2017.
We studied 156 physicians who tweeted a median of 584 times, with a 2014 median general payment totaling $13 600 (range 1000-444 100; table. Of these 156 physicians, 126 (81%) mentioned at least one drug from a company for which they had an FCOI. 137 (88%) physicians mentioned at least one drug for which they did not have an FCOI. Of 4358 total drug mentions, 2252 (52%) regarded conflicted drugs. Only two (1·3%) of the 156 individuals included disclosures of their payments, and these were in their 5-line twitter biography. When we compared 100 tweets about conflicted drugs with 100 tweets about non-conflicted drugs coded at random, conflicted tweets were more likely to be positive (66 vs 50; p=0·02), similarly likely to be neutral (35 vs 30, p=0·45), and less likely to be negative (4 vs 15; p=0·008).
Thus, we found that a majority of physicians on Twitter with significant financial conflict and frequent tweets mention specific drugs for which they have a conflict; and almost none disclose financial ties. Although these physicians also tweet about drugs for which they have no conflict, comparing these 3 In their Comment, these authors argued that the two biolsimilar phase 3 trials did not have robust endpoints.
These trials were both part of an extensive similarity exercise, which is typical for the development pathway of biosimilars. This pathway is different from that of traditional innovative medicines. In this Correspondence, we will briefly explain the biosimilarity pathway as it has evolved over the past 10 years with great success in the European Union.
Biosimilarity is established in a stepwise approach. The proposed biosimilars are tested in preclinical studies up to beyond doubt as being almost indistinguishable to the originator biological in physicochemical characterisation (eg, primary structure, glycosylation, heterogeneity, posttranslational modifications, and purity) and biological characterisation (for rituximab biosimilar: target and receptor binding, apoptosis, complement mediated cytotoxicity, and antibody-dependent cellular toxicity). It is followed by pharmacokinetics (PK) and pharmacodynamics (PD), toxicity, and efficacy studies done on animal models, confirming the similarity.
Subsequently, for the development of the rituximab biosimilar, clinical trials were done to confirm similarity in safety, PK and PD, and efficacy. First, a rather traditional bioequivalence trial confirmed bioequivalence and second, a phase 3 confirmatory trial showed the molecule did not behave differently from the reference product in patients. The endpoints were selected to be the most sensitive to show up any difference, in case there was one. Therefore, adequate endpoints may differ from innovator trials. 4 This research was done on the basic assumption that if the molecules are the same, they should have a similar effect on patients.
Rheumatoid arthritis is the best model for investigating PK and PD, because of the rituximab dosing schedule and the relatively low variability in peripheral blood B-lymphocyte counts. Efficacy in rheumatoid arthritis was assessed with disease activity score. Indication extrapolation is an important feature in biosimilar development. 5 In oncology, biosimilar trials have been done in follicular lymphoma, a well defined entity, for which the role of rituximab is undisputable, especially when combined with cyclophosphamide, vincristine, and prednisolone chemotherapy. The response rate chosen as a primary target is fully acceptable to confirm biosimilarity since it constitutes the most sensitive endpoint to compare the different molecules.
In our opinion it is rather disappointing that the special biosimilar development pathway was underexposed in the Comment 3 to the two largest biosimilar trials in oncology.
1,2 The problem is not about having a different opinion, and reading and interpreting clinical trial data differently; it is about having a new and different concept of drug development and of how to obtain evidence for similarity. It is important for clinicians to understand the scientific foundations of biosimilar development to appreciate the full potential for access to treatment and for great savings in health-care cost.
